Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study observed hair shedding in an 8 1/2-year-old girl treated with carbamazepine, which ceased after stopping the medication.

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.

This report describes a case where a man developed reversible myalgia and significant hyperCKemia after long-term finasteride use for male frontal baldness, with symptoms resolving upon discontinuation.

This article discusses suspected skin toxicity from drugs used to treat rheumatoid arthritis but reports no new clinical findings.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

In this study, a 33-year-old HIV-infected man experienced alopecia areata after beginning zidovudine therapy, which reversed upon discontinuation.

This paper reports a case of alopecia triangularis congenita in a 22-year-old woman, combined with androgenetic alopecia, and highlights successful treatment with internal and topical antiandrogens.

Oral cyclosporin doesn't stop hair loss.

Spironolactone can cause side effects like high potassium levels and breast enlargement, and patients need careful monitoring.

T cells and bacteria in the gut and skin help maintain health and protect against disease.

This review discusses the development and rapid approval of COVID-19 vaccines and notes the observation of autoimmune disorders, such as alopecia areata, following vaccination; it provides no new clinical results.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

More research, better treatments, and public education are needed for dermatological conditions in people of African descent.

In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.

This review discusses various adverse drug reactions affecting the skin, hair, and nails, emphasizing the importance of recognizing and reporting these reactions but reports no new clinical findings.

This case study reported an improvement in lower limb edema for a patient with type 2 diabetes mellitus after starting dulaglutide treatment, suggesting a potential role of the drug in sodium retention disorders.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This review focuses on the immunologic-based skin conditions that can result from β-blocker use, emphasizing potential adverse dermatologic effects rather than their therapeutic benefits.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This article reviews evidence- and consensus-based recommendations for using pegvaliase in adults with PKU and reports no new clinical results.

This review provides an overview of the prevalence and management of side effects of mood-stabilizing drugs in bipolar disorder patients and reports no new clinical results.

This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

This article discusses the potential for severe adverse cutaneous drug reactions with mood-stabilizing agents, emphasizing the importance of monitoring and patient communication, but reports no new clinical findings.

This study observed that combination therapy with prednisolone and azathioprine provided similar outcomes to prednisolone alone for treating pemphigus foliaceus in dogs, with over half achieving remission and significant improvement in another 25%.